Vermont Medicaid and GLP-1s

What changed, and what the document says

1. The exclusion, up front

   Not covered

   Three categories, one sentence, in the notes that introduce the whole list.

   “Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”

   Department of Vermont Health Access, Pharmacy-Benefit Management Program — Updated: 8/1/2026

2. The diabetes class

   Context

   Every drug in it, preferred or not, needs the diagnosis first.

   “Clinical criteria for all drugs: patient has a diagnosis of Type 2 Diabetes Mellitus.”

   Department of Vermont Health Access, Pharmacy-Benefit Management Program — Updated: 8/1/2026

3. The qualifier that carries Wegovy

   Conditions apply

   Five words, and they're what let a drug excluded on page one appear as preferred on page fifty.

   “Medication is not being used for weight loss only”

   Department of Vermont Health Access, Pharmacy-Benefit Management Program — Updated: 8/1/2026

4. And you can't have diabetes

   Conditions apply

   The cardiovascular route is written for people the diabetes class doesn't cover.

   “Patient does not have diagnosis of diabetes”

   Department of Vermont Health Access, Pharmacy-Benefit Management Program — Updated: 8/1/2026

5. Zepbound's number

   Conditions apply

   A sleep study with a threshold on it, plus a BMI floor and a CPAP prescription already in hand.

   “Zepbound: Patient has a diagnosis of obstructive sleep apnea (OSA) demonstrated by a sleep study with an AHI (events per hour) > 15 and meets the following criteria:”

   Department of Vermont Health Access, Pharmacy-Benefit Management Program — Updated: 8/1/2026

6. CPAP first

   Conditions apply

   Not a suggestion in the criteria. A condition listed alongside the BMI floor.

   “Has been prescribed CPAP therapy”

   Department of Vermont Health Access, Pharmacy-Benefit Management Program — Updated: 8/1/2026

7. How many people this reaches

   Context

   A count from the state's own review board, over ten months of claims.

   “A total of 1,183 members initiated GLP-1 RA therapy during the analysis period.”

   Department of Vermont Health Access, Drug Utilization Review Board — May 14, 2026

8. And how the two exceptions split

   Context

   Almost nine in ten of those starts were for diabetes. The Wegovy route accounted for four in a thousand.

   “GLP 1 RA utilization was primarily driven by T2DM (87.6%), with smaller proportions for OSA treated with Zepbound (12.0%) and minimal use for MACE risk reduction with Wegovy (0.4%).”

   Department of Vermont Health Access, Drug Utilization Review Board — May 14, 2026

Which of these companies serve Vermont?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

20 of those lists name Vermont: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, MEDvidi, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.